Intellia Therapeutics, Inc. (NTLA) financial statements (2022 and earlier)

Company profile

Business Address 40 ERIE STREET
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
SIC 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments74959728059341273
Cash and cash equivalents1231605759341273
Short-term investments625437223   
Receivables2258106
Prepaid expense1     
Other undisclosed current assets1717525942
Total current assets:769617289325355281
Noncurrent Assets
Operating lease, right-of-use asset793919
Property, plant and equipment211618171511
Long-term investments and receivables395 5   
Long-term investments395 5   
Other noncurrent assets 53567
Other undisclosed noncurrent assets30     
Total noncurrent assets:5256045222118
TOTAL ASSETS:1,294676334347376299
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities533617131011
Accounts payable10104325
Accrued liabilities4326131186
Deferred revenue642313
Debt  6   
Deferred revenue and credits2120
Contract with customer, liability27
Other undisclosed current liabilities96    
Total current liabilities:1266436413131
Noncurrent Liabilities
Long-term debt and lease obligation653413   
Operating lease, liability653413
Liabilities, other than long-term debt635116294458
Deferred revenue and credits4458
Deferred revenue635116
Contract with customer, liability29
Other liabilities   000
Total noncurrent liabilities:1288529294458
Total liabilities:25414964697689
Stockholders' equity
Stockholders' equity attributable to parent1,040527270278301210
Common stock000000
Additional paid in capital1,746962570479422263
Accumulated other comprehensive income (loss)(3)00(0)  
Accumulated deficit(703)(435)(301)(201)(121)(54)
Total stockholders' equity:1,040527270278301210
TOTAL LIABILITIES AND EQUITY:1,294676334347376299

Income statement (P&L) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues335843302616
Revenue, net2616
Revenue from related parties6   
Gross profit:335843302616
Operating expenses(301)(195)(149)(121)(96)(49)
Operating loss:(268)(137)(106)(91)(70)(32)
Nonoperating income127621
Investment income, nonoperating127621
Loss from continuing operations before equity method investments, income taxes:(267)(134)(100)(85)(68)(32)
Income from equity method investments1     
Loss before gain (loss) on sale of properties:(265)(134)(100)(85)(68)(32)
Other undisclosed net loss(3)     
Net loss available to common stockholders, diluted:(268)(134)(100)(85)(68)(32)

Comprehensive Income ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(268)(134)(100)(85)(68)(32)
Comprehensive loss:(268)(134)(100)(85)(68)(32)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(3)(0)0(0)  
Comprehensive loss, net of tax, attributable to parent:(271)(134)(99)(85)(68)(32)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: